Human Immunology News 6.13 April 3, 2018 | |
| |
TOP STORYInvestigators postulated that myelopoiesis might impact conventional dendritic cells (cDC) development. The cDC subset, cDC1, which includes human CD141+ DCs and mouse CD103+ DCs, supports anti-tumor immunity by stimulating CD8+ T-cell responses. To understand how cDC1 development changes during tumor progression, they investigated cDC bone marrow progenitors. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CXCL16 derived from first-trimester trophoblast cells induced the polarization of human M2 macrophages (MΦs). The M2 MΦ polarized by CXCL16 exhibited decreased interleukin-15 production, which facilitated the inactivation of natural killer (NK) cells. [Cell Mol Immunol] Full Article The authors performed an extensive examination of B-cell subsets and their proinflammatory properties in a Chinese cohort of new-onset systemic lupus erythematosus (SLE) patients. They observed that SLE patients exhibited an increased frequency of transitional B cells compared with healthy donors and rheumatoid arthritis patients. [Cell Mol Immunol] Abstract Scientists proved extracellular vesicle (EV) binding and uptake by THP-1 cells. Cellular origin and protein cargo of circulating preeclampsia-associated-EVs were characterized by flow cytometry and mass spectrometry. [Sci Rep] Full Article Researchers observed that fusion protein (FP) retained its antiprotease activity and that at equimolar amount of proteins, FP was more efficient than secretory leukocyte proteinase inhibitor (SLPI) in the inhibition. Both, FP and SLPI inhibited IL-2-induced lymphocyte proliferation, however, lower amounts of FP were required to achieve this inhibition. [Sci Rep] Full Article Excessive Activated T-Cell Proliferation after Anti-CD19 CAR T-Cell Therapy Excessive activated T-cell proliferation was observed in vivo in one patient after an anti-CD19-chimeric antigen receptor (CAR) T-cell infusion. [Gene Ther] Abstract Researchers aimed to reveal the circulating cell profile and the relative programmed cell death-1 (PD-1)/programmed cell death-1 ligand (PD-L1) expression of juvenile idiopathic arthritis subsets, elucidating their underlying immunomodulatory mechanisms. [Joint Bone Spine] Abstract The authors showed that, unlike in mice, DEC1/STRA13 expression is induced in human naïve and memory resting B cells by activation through the B-cell receptor or Toll-like receptor 9. [Immunol Lett] Abstract Researchers investigated the effect of human amniotic membrane extract on the pattern of cytokine production by T cells, monocytes and myeloid dendritic cells. [Cell Tissue Res] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSDevelopment of Mucosal-Associated Invariant T (MAIT) Cells Scientists discuss how MAIT cells transition through a three-stage development pathway in both mouse and human thymus, and continue to mature and expand after they leave the thymus. Moreover, they explore and speculate on how specific factors regulate different stages of this process. [Immunol Cell Biol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSbluebird bio, Inc. and Celgene Corporation announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States. [bluebird bio, Inc.] Press Release Pfizer Inc. and Allogene Therapeutics, Inc. announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer. [Pfizer Inc.] Press Release | |
| |
POLICY NEWSCancer Researchers Push to Relax Rules for Clinical Trials US government examines whether criteria for participating in drug studies unnecessarily exclude some people. [Nature News] Editorial EU Copyright Reforms Draw Fire from Scientists An influential committee of the European Parliament is due to vote on changes to copyright regulations in the European Union (EU), but the latest drafts of the rules have triggered a wave of criticism from open-science advocates. They say that the proposals will stifle research and scholarly communication. [Nature News] Editorial French Universities Cancel Subscriptions to Springer Journals French research organizations and universities have canceled their subscriptions to Springer journals, due to an impasse in fee negotiations between the publisher and Couperin.org, a national consortium representing more than 250 academic institutions in France. [The Scientist] Editorial In Emotional Speech, CDC’s New Leader Vows to Uphold Science Robert Redfield Jr., the new director of the Centers for Disease Control and Prevention (CDC), gave a deeply personal agency-wide address in which he repeatedly underscored the importance of science and data and said the CDC’s most critical public health mission is to protect Americans “from that which we don’t expect”. [The Washington Post] Editorial Cancer Researcher at the Ohio State University Resigns following Multiple Misconduct Findings A cancer researcher has resigned from The Ohio State University in Columbus after the institution determined he had committed misconduct in eight papers. His work in designing anticancer compounds had led to millions of dollars in funding and multiple patents, as well as two compounds in clinical trials. [ScienceInsider] Editorial
| |
EVENTSNEW 23rd Congress of European Hematology Association (EHA) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Scientist – Biomarker Development (Kymab) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Position – Onco-ImmunoMetabolism (San Raffaele Scientific Institute) Assistant/Associate Professor – Immunology (Saint Louis University) Postdoctoral Position – Immune Oncology (H. Lee Moffitt Cancer & Research Institute) Scientist – Immune Tolerance (Moderna Therapeutics) Postdoctoral Fellow – Immunology and iPSCs (Stanford University) Postdoctoral Research Associate – Immunity and Inflammation (University of Illinois) Principal Scientist – Immunosciences Drug Discovery (Bristol-Myers Squibb) Postdoctoral Fellow – T-Cell Therapy (Memorial Sloan Kettering Cancer Center) Senior Director – Immuno-Oncology Research (Alector LLC) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|